The United States medical research landscape is currently facing a period of significant fiscal instability as Congress struggles to finalize a full-year spending bill for the 2026 fiscal year (FY 2026). At the center of this budgetary deadlock is the National Institutes of Health (NIH), the primary federal agency responsible for biomedical and public health research. As the current fiscal cycle progresses without a permanent funding solution, the Endocrine Society has emerged as a leading voice in a broad coalition of scientific and patient advocacy groups calling for immediate legislative action. The ongoing uncertainty has already begun to hamper the NIH’s ability to distribute new research grants, creating a ripple effect that threatens to stall advancements in treatments for diabetes, obesity, thyroid disorders, and various hormone-related cancers.
The urgency of the situation is compounded by the looming transition into the next budget cycle. Even as FY 2026 remains unresolved, the Trump administration is expected to release its proposed budget for fiscal year 2027 in the coming weeks. This overlap creates a complex legislative environment where scientists and policymakers must simultaneously navigate the immediate needs of current research projects and the long-term strategic goals of the nation’s medical infrastructure. For the Endocrine Society and its thousands of member scientists, the stakes involve not only the continuity of laboratory work but also the broader health of the American public and the nation’s competitive edge in global biotechnology.
The Legislative Stalemate and the Impact of Continuing Resolutions
The primary cause of the current friction is the absence of a finalized appropriations bill for FY 2026. In the absence of such legislation, federal agencies often operate under Continuing Resolutions (CRs). While a CR prevents a total government shutdown by maintaining funding at previous year levels, it severely limits the flexibility of agencies like the NIH. Under a CR, the NIH is generally unable to launch new initiatives or significantly increase the number of grant awards, as the agency must remain cautious about its total obligations until a final budget is codified into law.
This "wait-and-see" approach has direct consequences for the scientific community. For researchers, particularly those at the early stages of their careers, the delay in grant approvals can mean the difference between maintaining a functioning laboratory and being forced to downsize staff or pause critical experiments. The Endocrine Society has noted that this instability discourages innovation and can lead to a "brain drain" where talented researchers leave academia for the private sector or move their operations to countries with more predictable funding environments.
Mobilizing the Scientific Community: The January Sign-On Letter
In response to the growing uncertainty, the Endocrine Society took a proactive leadership role in January by spearheading a massive organizational sign-on letter addressed to Congressional leadership. The letter was not merely a request for funds but a strategic document outlining the specific risks posed by the current budgetary climate. It garnered endorsements from more than 100 research institutions, medical professional societies, and patient advocacy organizations, demonstrating a unified front across the diverse spectrum of the American healthcare sector.
The coalition’s primary demand is the completion of a full-year appropriations bill for FY 2026 that includes a meaningful increase in funding for the NIH. However, the letter also addressed more technical, yet equally vital, aspects of federal grant management. One of the most significant concerns raised was the potential for administrative interference in the grantmaking process. Specifically, the Society and its partners urged Congress to prevent the administration from imposing arbitrary caps on negotiated facilities and administrative (F&A) cost rates.
F&A costs, often referred to as indirect costs, are the expenses associated with conducting research that cannot be easily attributed to a single project. These include the costs of maintaining high-tech laboratory facilities, utilities, hazardous waste disposal, and the administrative oversight required to ensure compliance with federal regulations. If the administration were to cap these rates arbitrarily, the financial burden would shift to universities and research hospitals, many of which are already operating on thin margins. Such a shift would likely result in a reduction in the total volume of research these institutions can support.
Addressing the Challenges of Forward-Funding
Another critical point of contention highlighted in the Endocrine Society’s advocacy efforts is the practice of "forward-funding." In an effort to manage budget fluctuations, the government sometimes funds the entire multi-year duration of a grant using current-year money. While this can provide security for the individual recipient, an excessive reliance on forward-funding during a period of budget constraints can drastically reduce the number of new grants the NIH can award in the short term.
The Endocrine Society has asked Congress to limit the number of forward-funded grants to levels consistent with previous years. This request aims to ensure that the maximum number of scientists can receive funding, thereby maintaining a healthy pipeline of diverse research projects. By spreading the available resources across a larger pool of "competing" grants (new or renewal grants), the NIH can continue to foster a wide range of scientific inquiries rather than concentrating resources in a smaller number of fully pre-paid projects.
Chronology of Advocacy and Budgetary Milestones
To understand the current urgency, it is helpful to look at the timeline of the federal budget process and the Society’s corresponding actions:
- Late 2025: Congressional negotiations for FY 2026 began to stall, leading to the implementation of temporary funding measures.
- January 2026: The Endocrine Society launched its coalition letter, bringing together 100+ organizations to lobby for a finalized NIH budget and protections against F&A caps.
- February 2026: Reports emerged that the Trump administration’s FY 2027 budget proposal would prioritize different spending areas, raising concerns about the future of the NIH’s base budget.
- March 13, 2026: The Endocrine Society scheduled its virtual "Researcher Hill Day," a strategic pivot from its traditional in-person advocacy model to a digital format designed to maximize participation.
- Spring 2026 (Anticipated): The release of the FY 2027 President’s Budget Request will officially kick off the next round of negotiations in the House and Senate Appropriations Committees.
The Strategic Pivot: Virtual Researcher Hill Day
A cornerstone of the Endocrine Society’s advocacy strategy is the annual "Hill Day," where scientists meet directly with members of Congress and their staff. Historically, this event has taken place in Washington, D.C., requiring participants to travel from across the country. However, for 2026, the Society has transitioned to a virtual format.
This shift to a "Virtual Researcher Hill Day" on March 13 is a calculated move to scale up engagement. By utilizing video conferencing platforms, the Society can involve a much larger and more geographically diverse group of members. This allows the organization to conduct more meetings in a single day and ensures that representatives from nearly every state can hear directly from the constituents who are conducting life-saving research in their home districts.
During these virtual meetings, member scientists are trained to provide more than just data; they share "impact stories." For example, a researcher in Ohio might explain how NIH-funded work on insulin signaling is leading to new therapies for the state’s high diabetic population, or a scientist in Florida might discuss how endocrine-disrupting chemicals are being studied to protect local water supplies. These narratives are essential for making the abstract numbers of a federal budget tangible to policymakers.
Data and Economic Implications of NIH Funding
The argument for robust NIH funding is supported by significant economic data. According to reports from United for Medical Research, every $1.00 of NIH funding generates approximately $2.46 in local economic activity. In 2023 alone, NIH funding supported more than 410,000 jobs across the United States and contributed nearly $93 billion to the GDP.
Beyond the direct economic impact, the NIH is the largest solicitor of basic research in the world. Basic research—the study of fundamental biological processes—is the foundation upon which the pharmaceutical and biotech industries build. Without the initial discoveries made in NIH-funded academic labs, the pipeline for new drugs and medical devices would effectively dry up. For the endocrine community, this is particularly relevant given the skyrocketing costs of treating chronic conditions like diabetes, which costs the U.S. healthcare system hundreds of billions of dollars annually. Investing in research that could lead to a cure or more efficient management of these diseases is viewed by many economists as a necessary cost-saving measure for the long term.
Official Responses and Political Climate
While the Endocrine Society leads the charge, the broader scientific community has echoed these concerns. Leadership from the Association of American Medical Colleges (AAMC) and the Federation of American Societies for Experimental Biology (FASEB) have similarly warned that "budgetary whiplash" is detrimental to the scientific enterprise.
On Capitol Hill, the NIH has historically enjoyed bipartisan support. However, the current political climate is defined by intense pressure to reduce federal spending and address the national debt. Some lawmakers have expressed a desire to see more "accountability" and "efficiency" in how the NIH allocates its funds, leading to the proposed caps on administrative costs that the Endocrine Society is currently fighting. The challenge for advocates is to demonstrate that these "efficiencies" could inadvertently dismantle the very infrastructure that makes high-level research possible.
Broader Impact and Future Outlook
As the March 13 Virtual Hill Day approaches, the Endocrine Society is calling on all its members to take action. The Society provides comprehensive training and materials to ensure that even those new to the political process can be effective advocates. The goal is to create a sustained drumbeat of communication that reminds Congress that medical research is not a partisan issue, but a national priority.
The outcome of the FY 2026 and FY 2027 negotiations will define the trajectory of American medicine for years to come. If the NIH budget is allowed to stagnate or if administrative hurdles are placed in the way of grantmaking, the pace of discovery will inevitably slow. Conversely, if the advocacy efforts of the Endocrine Society and its allies are successful, it could signal a renewed commitment to the scientific breakthroughs that improve the lives of millions of patients.
In the coming weeks, the focus will remain on the halls of Congress and the virtual meeting rooms of the Endocrine Society. The scientific community is making it clear: the cost of inaction is too high to ignore, and the time for a stable, robust federal investment in medical research is now.